{"title_page": "Coalition for Epidemic Preparedness Innovations", "text_new": "{{Other uses|CEPI (disambiguation)|Cepi (disambiguation)}}\n{{short description|Public-private organization for vaccine development}}\n{{Infobox organization\n| name                = Coalition for Epidemic Preparedness Innovations\n| logo                = CEPI.svg\n| motto               = ''New vaccines for a safer world''\n| abbreviation        = CEPI\n| formation           = {{start date and age|2017|01}}\n| headquarters        = [[Oslo]], Norway\n| coordinates         = \n| additional_location = {{bulleted list\n  | [[London]], [[UK]]\n  | [[Washington D.C.]], [[U.S.]]\n}}\n| purpose             = Fund vaccine development<ref name=FT/>\n| founding_location   = [[Davos]], Switzerland.<ref name=FT/> \n| founders             = {{bulleted list\n  | [[The Wellcome Trust]]\n  | [[Bill and Melinda Gates Foundation]].<ref name=FT/> \n}}\n| leader_title        = Chief executive\n| leader_name         = Richard J. Hatchett\n| leader_title2       = \n| leader_name2        = \n| board_of_directors  = \n| key_people          = [[Jane Halton]] (Chair)\n| main_organ          = \n| staff               = 68<ref name=BB>{{cite website|url=https://www.bloomberg.com/news/articles/2020-02-13/this-oslo-facility-may-be-the-key-to-the-coronavirus-vaccine | title=The Road to a Coronavirus Vaccine Runs Through Oslo | website=[[Bloomberg News]] | author=Peter Coy | date=13 February 2020 | accessdate=7 March 2020}}</ref>\n| staff_year          = 2020\n| website             = {{URL|https://cepi.net|CEPI.net}}\n}}\nThe '''Coalition for Epidemic Preparedness Innovations''' ('''CEPI''') is a foundation that takes donations from public, private, philanthropic, and [[civil society]] organisations, to finance independent research projects to develop [[vaccine]]s against [[emerging infectious disease]] (EID).<ref name=BB/><ref name=ER/> CEPI is focused on the [[World Health Organisation]]'s (WHO) \"[[blueprint priority disease]]s\", which includes: the [[Middle East respiratory syndrome-related coronavirus]] ([[MERS-CoV]]), the [[Severe acute respiratory syndrome coronavirus 2]] ([[SARS-CoV-2]]), the [[Nipah virus]], the [[Lassa fever virus]], and the [[Rift Valley fever]] virus, as well as the [[Chikungunya virus]] and the hypothetical, unknown pathogen \"[[Disease X]]\".<ref name=\"BUND\" /><ref name=\"ER\" /> CEPI investment also requires \"equitable access\" to the vaccines during [[outbreak|outbreaks]].<ref name=science/>\n\nCEPI was conceived in 2015 and formally launched in 2017 at the [[World Economic Forum]] (WEF) in [[Davos]], Switzerland.  It was co-founded and co-funded with US$460 million from the [[Bill and Melinda Gates Foundation]], [[The Wellcome Trust]], and a consortium of nations, being Norway, Japan, Germany; to which the European Union (2019) and Britain (2020) subsequently joined.<ref name=\"FT\" /><ref name=\"ER\" />  CEPI is headquartered in [[Oslo]], Norway.<ref name=FT/><ref name=BB/><ref name=ER/>  In 2017, ''[[Nature (journal)|Nature]]'' said, \"It is by far the largest vaccine development initiative ever against viruses that are potential epidemic threats\".<ref name=NAT/> In 2020, CEPI was identified as a \"key player in the race to develop a vaccine\" for the [[Coronavirus disease 2019]].<ref name=BB/><ref name=GUARD/><ref name=FT2/> \n\n==History==\n\n===Founding===\n[[File:Jeremy Farrar C0058569 Wellcome Images.jpg|thumb|upright=0.7|[[Jeremy Farrar]], co-author of the concept of CEPI, and board member]]\n\nThe concept for CEPI was outlined in a July 2015 paper in ''[[The New England Journal of Medicine]]'', titled \"Establishing a Global Vaccine-Development Fund\", co-authored by British medical researcher [[Jeremy Farrar]] (a director of [[Wellcome Trust]]), American physician [[Stanley A. Plotkin]] (co-discoverer of the [[Rubella]] vaccine), and American expert in infectious diseases [[Adel Mahmoud]] (developer of the [[HPV vaccine]] and [[rotavirus vaccine]]).<ref name=science/><ref>{{cite journal | title=Establishing a Global Vaccine-Development Fund | journal=[[The New England Journal of Medicine]] | date=23 July 2015 | author1=Stanley A. Plotkin | author2= Adel A.F. Mahmoud | author3=Jeremy Farrar | doi= 10.1056/NEJMp1506820 |pmid = 26200974| pages=297\u2013300 | volume=373|issue = 4}}</ref>\n\nTheir concept was further expanded at the 2016 WEF in Davos, where it was discussed as a solution to the problems encountered in developing and distributing a vaccine for the [[Western African Ebola virus epidemic]].<ref name=FT/>  Co-founder and funder, [[Bill Gates]] said: \"The market is not going to solve this problem because epidemics do not come along very often \u2014 and when they do you are not allowed to charge some huge premium price for the tools involved\".<ref name=FT/>  CEPI's creation was also supported and co-funded by the pharmaceutical industry including [[GlaxoSmithKline]] (GSK), with CEO [[Andrew Witty|Sir Andrew Witty]] explaining at the WEF, \"It is super-disruptive when the red phone rings in our vaccine division because of a health emergency.  People do not realise that there's no spare capacity in the world's vaccine production system today\".<ref name=FT/>\n\nCEPI was formally launched at the 2017 WEF in Davos, with an initial investment of US$460 million by a consortium that included the governments of Norway, Japan, and Germany, The Wellcome Trust, and the [[Bill and Melinda Gates Foundation|Gates Foundation]];<ref name=TIME>{{cite magazine | url=https://time.com/4639245/cepi-ebola-zika-epidemic/ | title=This New Group Wants to Stop Pandemics Before They Start | magazine=[[Time (magazine)|Time]] | author=Alexandra Sifferlin | date=19 January 2017}}</ref><ref name=FT>{{cite newspaper | url=https://www.ft.com/content/5699ac84-dd87-11e6-86ac-f253db7791c6 | title=Davos launch for coalition to prevent epidemics of emerging viruses | newspaper=[[Financial Times]] | author=Clive Cookson | date=18 January 2017 | accessdate=6 March 2020 | quote=Billion-dollar programme aims to cut vaccine-development time from 12 years to one}}</ref>  India joined a short time afterwards.<ref>{{cite news|first=James|last=Paton|date=January 18, 2017|url=https://www.bloomberg.com/news/articles/2017-01-18/ebola-zika-push-drugmakers-to-join-effort-to-avert-pandemics|title=Ebola, Zika Push Drugmakers Into Effort to Avert Pandemics|work=[[Bloomberg L.P.|Bloomberg]]}}</ref><ref name=economist>{{cite journal|journal=[[The Economist]]|title=Putting shots in the locker|date=3 September 2016|pages=67\u201368|volume=420|number=9003|url=https://www.economist.com/news/science-and-technology/21706240-how-anticipate-epidemics-putting-shots-locker}}</ref>  In a launch interview with the ''[[Financial Times]]'' (FT), Gates said that a key goal was to reduce the time to develop vaccines from 10 years to less than 12 months.<ref name=FT/>  The initial targets were the six EID viruses with known potential to cause major epidemics, being: [[Middle East respiratory syndrome|MERS]], [[Lassa fever]], [[Nipah virus]], [[Ebola]], [[Marburg fever]] and [[Zika]].<ref name=FT/><ref name=ER>{{cite journal | author1=Dimitrios Gouglas | author2= Mario Christodoulou | author3= Stanley A Plotkin | author4= Richard Hatchett | title=CEPI: Driving Progress Towards Epidemic Preparedness And Response | journal=[[Epidemiologic Reviews]] | doi=10.1093/epirev/mxz012 | pmid= 31673694 | date=November 2019}}</ref> The ''FT'' reported CEPI would \"build the scientific and technological infrastructure for developing vaccines quickly against pathogens that emerge from nowhere to cause a global health crisis, such as Sars in 2002/03 and Zika in 2015/16\", and fund research papers on the costs and process of vaccine development.<ref name=FT/> ''[[Town & Country (magazine)|Town & Country]]'' listed it as a \"Top 10 moment from Davos\".<ref>{{cite magazine | url=https://www.townandcountrymag.com/society/money-and-power/news/g3205/2017-davos-world-economic-forum/ | magazine=[[Town & Country (magazine)|Town & Country]] | title=The Top 10 Moments at the 2017 Davos World Economic Forum | author=Natalina Lopez | date=27 January 2017 | accessdate=13 March 2020}}</ref>\n\nAt launch, Norwegian physician [[John-Arne R\u00f8ttingen]], who led the steering committee for Ebola vaccine trials, served as interim CEO, and CEPI was based at the [[Norwegian Institute of Public Health]] in Olso.<ref name=science>{{cite journal|author=John Cohen|date=2 September 2016|title=New vaccine coalition aims to ward off epidemics|url=http://www.sciencemag.org/news/2016/09/new-vaccine-coalition-aims-ward-epidemics|journal=Science|volume=353|issue=6303}}</ref>\n\nIn April 2017, Richard J. Hatchett, former director of the U.S. government's [[Biomedical Advanced Research and Development Authority]] (BARDA), became the full-time CEO.<ref>{{cite journal| journal=[[International AIDS Vaccine Initiative|IAVIReport]] | url=https://www.iavireport.org/vol-21-no-1-2017/1879-an-interview-with-richard-hatchett | title=AN INTERVIEW WITH RICHARD HATCHETT | volume=21 | issue=1 | date=2017 |  author=Michael Dumiak}}</ref>  Hatchett was also a member of the [[United States Homeland Security Council]] under [[George W. Bush]], and the [[United States National Security Council]], under [[Barack Obama]].<ref name=FT2/><ref>{{cite website | url=https://www.lshtm.ac.uk/newsevents/events/richard-hatchett-lshtm | title=Richard Hatchett at LSHTM | website=[[London School of Hygiene & Tropical Medicine]] | accessdate=8 March 2020}}</ref>\n\nIn April 2017, CEPI opened an additional office in London, and in October 2017, a further office was opened in Washington D.C.<ref>{{cite website|title=Coalition for Epidemic Preparedness Innovations | url=https://cepi.net/about/whyweexist/ | accessdate=11 March 2020 | website=CEPI}}</ref>\n\n===Funding===\n[[File:Coalition for Epidemic Preparedness Innovations (2017, Davos).jpg|thumb|Launch during the 2017 WEF at Davos]]\n\nAt its launch in 2017, CEPI announced five-year financial pledges from its founders that amounted to US$460 million and came from the sovereign governments of Japan (US$125 million), Norway (US$120 million), and Germany (US$10.6 million in 2017 alone, and which later became US$90 million), and from global foundations of the Gates Foundation (US$100 million), and the Wellcome Trust (US$100 million); India was finalising their financial commitment, which was made shortly afterward.<ref name=WP2>{{cite newspaper | url=https://www.washingtonpost.com/news/to-your-health/wp/2017/01/18/new-global-coalition-launched-to-create-new-vaccines-prevent-epidemics/ | title=New global coalition launched to create vaccines, prevent epidemics | newspaper=[[Washington Post]] | author=Lena H. Sun | date=18 January 2017 | accessdate=12 March 2020}}</ref>  A funding target of US$1 billion was set for the first 5 years of operation (i.e. by January 2022).<ref name=WP2/>  The journal ''[[Nature (journal)|Nature]]'' said of the amount raised that: \"It is by far the largest vaccine development initiative ever against viruses that are potential epidemic threats\".<ref name=NAT>{{cite journal | title=Billion-dollar project aims to prep vaccines before epidemics hit | journal=[[Nature (journal)|Nature]] | date=18 January 2017 | doi=10.1038/nature.2017.21329 | pmid=28128262 | bibcode=2017Natur.541..444B | volume =541 | pages=444\u2013445| last1=Butler | first1=Declan | issue=7638 }}</ref>\n\nAs part of its funding structure, CEPI has used \"vaccine bonds\" to \"frontload\" multi-year sovereign funding pledges. In 2019, the [[International Finance Facility for Immunisation]] (IFFIm) issued NOK 600 million in vaccine bonds to front-load the commitment by Norway, through [[GAVI|Gavi, the Vaccine Alliance]], to CEPI.<ref>{{cite website | url=https://www.gavi.org/news/media-room/coalition-epidemic-preparedness-innovation-turns-iffim-accelerate-funding-new | title=Coalition for Epidemic Preparedness Innovation turns to IFFIm to accelerate funding for new vaccine development | date=12 December 2018 | website=[[GAVI]] | accessdate=8 March 2020 | quote=Under the just-approved arrangement, IFFIm will, on CEPI\u2019s behalf, issue bonds on international capital markets supported by new pledges from the Kingdom of Norway, which hosts CEPI. Norway and CEPI have turned to IFFIm because of its simplicity, speed of execution, cost, compliance and strong reputation among investors.}}</ref><ref>{{cite website | url=https://iffim.org/press-releases/iffim-issues-nok600-million-vaccine-bonds | title=IFFIm issues NOK600 million Vaccine Bonds | website=[[International Finance Facility for Immunisation]] | accessdate=8 March 2020 | date=18 July 2019}}</ref>\n\nIn March 2019, the [[European Commission]] granted access to CEPI into the EU's [[Horizon 2020]] programme, and a longer-term financial funding programme.<ref>{{cite website | url=https://cordis.europa.eu/programme/id/H2020_FPA-SC1-CEPI-2019 | website=[[European Commission]] | accessdate=9 March 2020 | date=19 March 2019 | title=FPA-SC1-CEPI-2019 - Grant to the Coalition for Epidemic Preparedness Innovations (CEPI) }}</ref>  CEPI note presentations that the EU's financial commitment amounts to US$200 million, which when added to the seed amount (including the full German commitment), came to US$740 million.<ref>{{cite website | url=https://www.uniteforsight.org/conference/ppt-2019/Dimitrios%20Gouglas%20PDF.pdf | title=[PRESENTATION] Coalition for Epidemic Preparedness Innovations | date=13 April 2019 | accessdate=12 March 2020 | author=Dimitrios Gouglas | website=[[Unite For Sight]]}}</ref>\n\nBy February 2020, ''[[Bloomberg News]]'' reported that CEPI had raised a total of US$760 million with additional donations from the governments of Australia, Belgium, Canada, and the U.K.<ref name=BB/>  ''Bloomberg'' said that \"CEPI solves what economists call a 'coordination problem'. It can help pair boutique research and development companies with big vaccine manufacturers, work with regulators to streamline approval processes and resolve patent disputes on the spot. Its scientific advisory committee has executives from Pfizer, Johnson & Johnson, and Japan's Takeda Pharmaceutical, among others\".<ref name=BB/>\n\nIn March 2020, the British government pledged \u00a3210 million in funding to CEPI to specifically focus on a vaccine for the coronavirus; making Britain CEPI's largest individual donor.<ref>{{cite newspaper | url=https://www.thetimes.co.uk/article/uk-promises-210m-to-find-coronavirus-vaccine-7883gcq7q | title=UK promises \u00a3210m to find coronavirus vaccine | author=Rhys Blakely | newspaper=[[The Times]] | date=27 March 2020 | accessdate=28 March 2020}}</ref><ref>{{cite newspaper | url=https://www.independent.co.uk/news/uk/politics/coronavirus-vaccine-boris-johnson-uk-donation-update-a9428566.html | title=Coronavirus: Britain now the largest contributor to international effort to find vaccine after \u00a3210m commitment | newspaper=[[The Independent]] | author=Andrew Woodcock | date=27 March 2020 | accessdate=28 March 2020}}</ref>\n\n===Equitable access===\nOne of the founding principles of CEPI is around what it calls \"equitable access\" by charging vaccines at affordable prices to developing nations.<ref name=BB/>  CEPI's original 18-page policy document gave  CEPI \"step-in\" rights to use the intellectual property of its partner companies in which it had invested, for vaccine production even if they withdrew from the CEPI agreement.<ref name=BB/>  However, part of this policy had to be later scaled back into a shorter, two-page, document in order to encourage more private sector partner companies to engage in vaccine research.<ref name=BB/>  CEPI came under criticism for this by [[M\u00e9decins Sans Fronti\u00e8res]], however, commentators expressed an opinion that this may have been an inevitable consequence to get higher engagement by the pharmaceutical industry in supporting vaccine development.<ref>{{cite newspaper | url=https://www.nytimes.com/2020/03/02/opinion/contributors/pharma-vaccines.html | title=Big Pharma May Pose an Obstacle to Vaccine Development | date=2 March 2020 | accessdate=8 March 2020 | newspaper=[[New York Times]] | author=Gerald Posner | quote=Drug companies on CEPI's scientific advisory panel, including Johnson & Johnson, Pfizer, and Japan's Takeda, pushed back. CEPI mostly capitulated in a December 2018 two-page declaration in which it jettisoned specifics but gave lip service to its founding mission of \"equitable access to these vaccines for affected populations during outbreaks.\"| author-link=Gerald Posner }}</ref>\n\n==Structure==\n[[File:Dr Richard J. Hatchett (2011).jpg|thumb|upright=0.7|Richard J. Hatchett, CEO of CEPI from 2017]]\nCEPI is a Norwegian Association, and had the following governance structure as at March 2020:<ref name=CEPI/><ref name=ER/>\n\n*Leadership. Staff of 68,<ref name=BB/> that runs the organisation on a day-to-day basis under the direction of a chief executive officer,  Richard Hatchett.<ref name=CEPI/>\n*Board. Twelve members, four from the Investors Council, and eight of which are \"independent members representing competencies including industry, global health, science, resource mobilisation, finance\".<ref name=CEPI/>  \n**[[Charlotte Watts]], chief scientific adviser to the U.K. [[Department for International Development]]\n**Cherry Gagandeep Kang, [[Christian Medical College & Hospital, Vellore]]\n**David Reddy, [[Medicines for Malaria Venture]]\n**Ichiro Kurane, National Institute of Infectious Diseases, Japan\n**Joachim Klein, [[Federal Ministry of Education and Research (Germany)]]\n**[[Jane Halton]], chairperson\n**[[Jeremy Farrar]], director of the Wellcome Trust\n**John Nkengasong, Africa Centers for Disease Control and Prevention\n**Nadine Gbossa, representative Nigeria, [[International Fund for Agricultural Development]]\n**Patricia J. Garc\u00eda, former [[Ministry of Health (Peru)|Minister of Health, Peru]]\n**[[Peter Piot]], [[London School of Hygiene & Tropical Medicine]]\n**Rajeev Venkayya, [[Takeda Pharmaceutical Company]]\n**(Attending board meetings are an additional five non-voting members that include: [[Helen Rees]], [[Muhammad Ali Pate]], [[Margaret Hamburg|Margaret \"Peggy\" Hamburg]], [[Soumya Swaminathan (scientist)|Soumya Swaminathan]], the CEPI CEO).<ref name=CEPI/>\n*Scientific Advisory Committee (SAC). 24 voting members that provide \"scientific support, advice, and guidance to the CEPI Board and Secretariat. Final decision-making about the issues addressed by the committee rests with the Board or the Secretariat\".  The SAC includes members such as [[Alash\u2019le Abimiku]], [[Christian Br\u00e9chot]], [[Delese Mimi Darko]], [[Helen Rees]], [[James C. Robinson (health economist)|James C. Robinson]] (vice-chair), [[Kathleen Neuzil]], {{ill|Myron M. Levine|de|Myron M. Levine}}, [[Peter Smith (epidemiologist)|Peter Smith]], [[Stanley Plotkin]], [[Thomas Kariuki]], and [[Yves L\u00e9vy]].  In addition, there are five non-voting members of the SAC, who each represent mostly industry, being [[Johnson & Johnson]], [[Takeda Pharmaceutical]], [[Pfizer]], and [[Sanofi Aventis]]; with the final non-voting member being from the WHO.<ref name=CEPI/>\n*Joint coordination group (JAG). The JAG is a \"roundtable of independent institutions with an interest in seeing CEPI\u2019s vaccines successfully developed and deployed in an outbreak\". Members of the JAG included the WHO, [[GAVI]], [[European Medicines Agency]], [[Food and Drug Administration]], [[M\u00e9decins Sans Fronti\u00e8res]], [[UNICEF]], [[International Federation of Red Cross and Red Crescent Societies]], African Vaccine Regulatory Forum, [[National Institute for Biological Standards and Control]], and The Wellcome Trust.<ref name=CEPI>{{cite website| url=https://cepi.net/about/whoweare/ | title=Who we are | website=Coalition for Epidemic Preparedness Innovations | accessdate=9 March 2020}}</ref>\n*Investors Council (IC). The IC nominates four investor representatives to the board, and its approval is required for single investments over US$100 million. The IC included representatives from the governments of Norway, UK, Germany, Japan, Canada, Ethiopia, Australia, Belgium, the EU, and the Gates Foundation and the Wellcome Trust.<ref name=CEPI/>\n\n==Publications==\nIn October 2018, CEPI published a study in British healthcare journal ''[[The Lancet]]'', that estimated the costs of developing vaccines for diseases that could escalate into global humanitarian crises.  The study focused on 11 diseases which cause relatively few deaths at present and primarily strike the poor. The authors estimated that it would cost between US$2.8 billion and US$3.7 billion to develop at least one vaccine for each of the diseases. This should be set against the potential cost of an outbreak. The 2003 SARS outbreak in East Asia cost US$54 billion.<ref>{{cite news |title=Scientists have estimated the cost of stopping 11 diseases that could kill millions in a pandemic |url=https://www.vox.com/future-perfect/2018/10/22/17999676/vaccine-ebola-pandemic-disease-zika-epidemic-sars?platform=hootsuite |accessdate=2 December 2018 |publisher=Vox |date=22 October 2018}}</ref><ref>{{cite journal | url=https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(18)30346-2/fulltext | title=Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study | journal=The Lancet | year=2018 | volume=6 | issue=12 | pmid=30342925 | last1=Gouglas | first1=D. | last2=Thanh Le | first2=T. | last3=Henderson | first3=K. | last4=Kaloudis | first4=A. | last5=Danielsen | first5=T. | last6=Hammersland | first6=N. C. | last7=Robinson | first7=J. M. | last8=Heaton | first8=P. M. | last9=R\u00f8ttingen | first9=J. A. | pages=e1386\u2013e1396 | doi=10.1016/S2214-109X(18)30346-2 }}</ref>\n\nIn November 2019, CEPI published a paper in the German healthcare journal ''{{ill|Bundesgesundheitsblatt|de|Bundesgesundheitsblatt}}'', discussing the structure and operation of CEPI and that its target portfolio was on the [[World Health Organisation|WHO]]'s \"[[blueprint priority disease]]s\", that included: MERS-CoV, Nipah virus, Lassa fever virus, and [[Rift Valley fever]] virus, as well as [[Chikungunya virus]], and the WHO's [[Disease X]].<ref name=BUND>{{cite journal | title=Developing vaccines against epidemic-prone emerging infectious diseases | journal=Bundesgesundheitsblatt | pages=65\u201373 | volume=63 | doi=10.1007/s00103-019-03061-2| pmid=31776599 | pmc=6925075 |year = 2020|last1 = Bernasconi|first1 = Valentina|last2 = Kristiansen|first2 = Paul A.|last3 = Whelan|first3 = Mike|last4 = Rom\u00e1n|first4 = Ra\u00fal G\u00f3mez|last5 = Bettis|first5 = Alison|last6 = Yimer|first6 = Solomon Abebe|last7 = Gurry|first7 = C\u00e9line|last8 = Andersen|first8 = Svein R.|last9 = Yeskey|first9 = Debra|last10 = Mandi|first10 = Henshaw|last11 = Kumar|first11 = Arun|last12 = Holst|first12 = Johan|last13 = Clark|first13 = Carolyn|last14 = Cramer|first14 = Jakob P.|last15 = R\u00f8ttingen|first15 = John-Arne|last16 = Hatchett|first16 = Richard|last17 = Saville|first17 = Melanie|last18 = Norheim|first18 = Gunnstein| issue=1 }}</ref>\n\nIn November 2019, CEPI also published a paper in the healthcare journal ''[[Epidemiologic Reviews]]'', outlining all of the projects they had invested in and their scientific and medical rationale.  The paper also updated CEPI's priorities saying that in addition to investing in vaccines for its target portfolio, it also wanted to fund the establishment of technical and regulatory pathways for vaccine development, develop sustainable manufacturing solutions for vaccine candidates nearing completion, and create investigational stockpiles of its vaccine candidates for use in emergency situations.<ref name=ER/>\n\n==Investments==\n\nMost of CEPI's work is performed by allocating funds to independent third-party laboratories and vaccine research organizations through investments, the most material ones being:<ref name=BB/><ref name=ER/>\n\n===General development===\n\nIn December 2018, US$8.4 million to [[Imperial College]] in London, to fund the development of a \"self-amplifying RNA vaccine platform\" that CEPI said: \"would enable a tailored vaccine production against multiple viral pathogens (including H1N1 influenza, rabies virus, and Marburg virus)\".<ref name=ER/>  \t\n\nIn December 2018, US$10.6 million was given to the [[University of Queensland]] to fund the development of a \"[[molecular clamp]]\" vaccine platform, that CEPI described as a \"transformative technology that enables targeted and rapid vaccine production against multiple viral pathogens (including influenza virus, MERS-CoV, and respiratory syncytial virus)\".<ref name=ER/> \t\n\nIn February 2019, US$34 million was given to the German-based [[CureVac]] [[biopharmaceutical]] company, to fund the development of an \"RNA Printer prototype\", which CEPI described as being a \"transportable, down-scaled, automated [[mRNA]] printing facility, that can produce rapidly, a supply of lipid-nanoparticle\u2013formulated mRNA vaccine candidate that can target known pathogens (including Lassa fever, yellow fever, and rabies); and prepare for rapid response to unknown pathogens (i.e., [[Disease X]])\".<ref name=ER/>\n\n===Specific vaccines===\n\n====Lassa fever/MERS-CoV====\n[[File:Lassa virus.JPG | thumb | [[Transmission electron microscopy|TEM]] of [[Lassa fever|Lassa]] [[virions]]]]\nIn March 2018, US$37.5 million was given to Austrian-based Themis Bioscience to fund a vaccine against Lassa virus and MERS-CoV, using a measles vector technology.<ref>{{Cite news|url=https://www.businesswire.com/news/home/20180306005125/en/CEPI-Partners-Themis-Bioscience-Advance-Vaccines-Lassa|title=CEPI Partners with Themis Bioscience to Advance Vaccines Against Lassa Fever and MERS \u2013 Press Release|access-date=2018-04-15|language=en}}</ref><ref name=ER/>\n\nIn April 2018, US$56 million was given to U.S.-based [[Inovio Pharmaceuticals]] to fund a DNA-vaccine against Lassa virus and MERS-CoV.<ref>{{Cite news|url=https://globenewswire.com/news-release/2018/04/11/1468470/0/en/Inovio-Awarded-up-to-56-Million-from-CEPI-to-Advance-DNA-Vaccines-Against-Lassa-Fever-and-MERS.html|title=Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS \u2013 Press Release|work=GlobeNewswire News Room|access-date=2018-04-15|language=en-US}}</ref><ref name=ER/>\n\nIn May 2018, US$54.9 million was given to the [[International AIDS Vaccine Initiative]] (IAVI), to fund a vaccine against Lassa virus via replication-competent vesicular stomatitis [[viral vector]] technology.<ref name=ER/>\n\nIn June 2018, US$35 million was given to U.S.-based Profectus Biosciences, to fund an attenuated \"VesiculoVax\" vaccine against Lassa virus.<ref name=ER/>\n \nIn August 2018, US$36 million was given to German-based {{ill|IDT Biologika|de|IDT Biologika}}, to fund a vaccine against MERS-CoV (only) using a recombinant modified vaccinia Ankara viral vector technology.<ref name=ER/>\n \nIn September 2018, US$19 million to [[Janssen Pharmaceutica]] and the [[University of Oxford]], to fund a vaccine against Lassa and MERS-Cov using a simian adenoviral vaccine viral vector technology.<ref name=ER/>\n\n====Nipah virus====\n[[File:Nipah.jpg | thumb | [[Transmission electron microscopy|TEM]] of [[Nipah virus|Nipah]] [[virions]]]]\n\nIn May 2018, US$25 million was given to U.S.-based Profectus Biosciences, to make a recombinant [[protein subunit]] vaccine against Nipah virus.<ref name=ER/>\n\nIn February 2019, US$31 million was given to the [[University of Tokyo]], to develop a vaccine by inserting the Nipah-virus G gene (\"Malaysia strain\"), into a measles vector (\"Edmonston B strain\").<ref name=ER/>\n\nIn August 2019, US$43.6 million was given to Public Health Vaccines LLC, to fund the development and manufacture of a vaccine using a recombinant vesicular stomatitis virus technology.<ref>{{cite website | url=https://cepi.net/news_cepi/cepi-awards-up-to-us43-6-million-to-public-health-vaccines-llc-for-development-of-a-single-dose-nipah-virus-vaccine-candidate/ | website=CEPI | date=19 August 2019 | accessdate=9 March 2020 | title=CEPI awards up to US$43.6 million to Public Health Vaccines, LLC. for development of a single-dose Nipah virus vaccine candidate}}</ref><ref name=ER/>\n\n====SARS-CoV-2====\n{{see also|2019\u201320 coronavirus pandemic|Coronavirus disease 2019#Research}}\n[[File:SARS-CoV-2 49531042877.jpg|thumb|[[Scanning electron microscope|SEM]] of [[SARS-CoV-2]]]]\n\nIn January 2020, CEPI funded three teams working on a [[COVID-19 vaccine|vaccine]] for [[SARS-CoV-2]], being: [[Moderna]], [[Inovio Pharmaceuticals]], and the [[University of Queensland]] (UQ).<ref name=\"ThomReut_NIH_Moderna_3months\" /><ref name=\"Guardian_CEPI_16weeks\" /> By February 2020, Inovio announced that it had produced a pre-clinical [[DNA vaccination|DNA-based vaccination]] to fight [[COVID-19]] at its lab in [[San Diego]].<ref>{{cite web |title=Is a vaccine for the coronavirus coming? Inovio says it has designed one in San Diego |url=https://www.latimes.com/business/story/2020-02-15/coronavirus-vaccine-design-inovio-san-diego |website=[[Los Angeles Times]] |date=15 February 2020 |accessdate=17 February 2020}}</ref> Inovio collaborated with a Chinese firm to speed its acceptance by regulatory authorities in China for human trialing.<ref>{{Cite news |url=https://www.bbc.com/news/health-51299735 |title=Coronavirus: Scientists race to develop a vaccine |last=Mazumdar |first=Tulip |date=30 January 2020|website=[[BBC News Online]]|access-date=3 February 2020|archive-url=https://web.archive.org/web/20200130184311/https://www.bbc.com/news/health-51299735 |archive-date=30 January 2020 |url-status=live | name-list-format=vanc}}</ref> The strategy of the UQ team is to develop a [[molecular clamp]] vaccine that genetically modifies viral proteins to make them mimic the coronavirus and stimulate an immune reaction.<ref name=\"Guardian_CEPI_16weeks\" /><ref name=\"ThomReut_NIH_Moderna_3months\" />\n\nIn January 2020, CEPI announced a fourth SARS-CoV-2 project in a collaboration with their existing partner [[CureVac]], to develop and manufacture a vaccine.<ref>{{cite news |title=CureVac and CEPI extend their Cooperation to Develop a Vaccine against Coronavirus nCoV-2019 |url=https://www.curevac.com/news/curevac-and-cepi-extend-their-cooperation-to-develop-a-vaccine-against-coronavirus-ncov-2019 |accessdate=25 February 2020 |publisher=CureVac AG |date=31 January 2020}}</ref>  CEPI's CEO, Richard J. Hachett said in an interview with the ''FT'' that CEPI expected to have human trials within 16 weeks, but cautioned \"All these timelines are aggressive and aspirational. As circumstances unfold there may be opportunities to reduce the timing but it is critically important that any new vaccine is safe and effective\".<ref name=FT2>{{cite newspaper | url=https://www.ft.com/content/40abf052-41e9-11ea-bdb5-169ba7be433d | title=The scientist leading the coronavirus vaccine race | newspaper=[[Financial Times]] | date=30 January 2020 | accessdate=8 March 2020 | author=Hannah Kuchler}}</ref>\n\n[[File:2019-nCoV-CDC-23312 without background.png |thumb|[[Morphology (biology)|morphology]] of [[coronavirus]]]]\n\nIn February 2020, ''Bloomberg News'', citing [[virologists]], identified CEPI as a \"key player in the race to develop a vaccine\";<ref name=BB/> a status other media outlets have attributed.<ref>{{cite website | url=https://www.businessinsider.com/vaccines-for-wuhan-china-cornonavirus-moderna-inovio-cepi-2020-1?r=US&IR=T | title=A coalition backed by Bill Gates is funding biotechs that are scrambling to develop vaccines for the deadly Wuhan coronavirus | author=Andrew Dunne | website=[[Business Insider]] | date=23 January 2020 | accessdate=8 March 2020}}</ref><ref name=FT2/>  In reviewing vaccine development on the virus ''[[Vox (website)|Vox]]'' said: \"CEPI is a large part of why there are already dozens of Covid-19 vaccine candidates making their way through animal and human trials, as well as platforms to develop more\",<ref>{{cite magazine | url=https://www.vox.com/science-and-health/2020/3/4/21154590/coronavirus-vaccine-treatment-covid-19-drug-cure | title=A simple guide to the vaccines and drugs that could fight coronavirus | magazine=[[Vox (website)|Vox]] | date=6 March 2020 | accessdate=8 March 2020 | author1=Julia Belluz | author2= Umair Irfan | author3= Brian Resnick | quote=Knowing there will be more Ebola-like emergencies in need of ready vaccines was the starting point for the Coalition for Epidemic Preparedness Innovations, or CEPI, a public-private partnership that launched in 2017. Their raison d\u2019\u00eatre: to award grants for swift vaccine development targeting emerging threats that the pharmaceutical industry might otherwise ignore.}}</ref> while ''[[The Guardian]]'' said CEPI was \"leading efforts to finance and coordinate Covid-19 vaccine development\".<ref name=GUARD>{{cite newspaper | url=https://www.theguardian.com/world/2020/mar/15/when-will-a-coronavirus-vaccine-be-ready-human-trials-global-immunisation | title=When will a coronavirus vaccine be ready? | newspaper=[[The Guardian]] | date=15 March 2020 | accessdate=15 March 2020 | author=Laura Spinney | quote=\"The speed with which we have [produced these candidates] builds very much on the investment in understanding how to develop vaccines for other coronaviruses\", says Richard Hatchett, CEO of the Oslo-based nonprofit the Coalition for Epidemic Preparedness Innovations (Cepi), which is leading efforts to finance and coordinate Covid-19 vaccine development.}}</ref>\n\nIn March 2020, Hatchett gave an interview to ''[[Channel 4 News]]'' saying that \"war is an appropriate analogy\", for the steps needed to counter the virus, and that \"this is the most frightening disease that I have ever encountered in my career, and that includes Ebola, it includes MERS, it includes SARS. And it's frightening because of the combination of infectiousness and a lethality that appears to be manyfold higher than flu\".<ref>{{cite website | url=https://www.channel4.com/news/this-is-the-most-frightening-disease-ive-ever-encountered-virus-expert-dr-richard-hatchett | quote=Dr. Richard Hatchett advised the Bush and Obama White Houses and worked for the agency that protects Americans against pandemics and bioweapons. | title='This is the most frightening disease I've ever encountered' \u2013 virus expert Dr. Richard Hatchett | author=Matt Frei | website=[[Channel 4 News]] | date=6 March 2020 | accessdate=8 March 2020 | series=Interview on C4 News [VIDEO]| author-link=Matt Frei }}</ref>  Hatchett told ''[[The Daily Telegraph]]'' that coronaviruses are the most serious threat to public health since the [[Spanish flu]], and that a vaccine will take up to 18 months to deliver at a cost of \u00a31.5 billion.<ref>{{cite newspaper|url=https://www.telegraph.co.uk/news/2020/03/06/coronavirus-poses-serious-threat-public-health-since-spanish/ | title=Coronavirus poses most serious threat to public health since Spanish flu pandemic, says expert | newspaper=[[Daily Telegraph]] | author=Robert Mendick | date=6 March 2020 | accessdate=7 March 2020}}</ref>    CEPI said that its funds for fighting the virus would be fully allocated by the end of March and that it was launching a new funding call for US$2 billion to support fighting the virus.<ref>{{cite website| url=https://www.reuters.com/article/us-health-coronavirus-vaccines/2-billion-needed-to-develop-covid-19-shot-says-epidemic-response-group-idUSKBN20T28H | title=$2 billion needed to develop COVID-19 shot, says epidemic response group | author=Kate Kelland | date=6 March 2020 | accessdate=7 March 2020 | website=[[Reuters News]]}}</ref><ref>{{cite newspaper | url=https://www.ft.com/content/e0ecc6b6-5d43-11ea-b0ab-339c2307bcd4 | title=Coronavirus and the $2bn race to find a vaccine | newspaper=[[Financial Times]] | date=5 March 2020 | accessdate=7 March 2020 | author=Hannah Kultcher}}</ref><ref>{{cite website | url=https://www.bloomberg.com/news/articles/2020-03-06/coronavirus-vaccine-work-faces-funding-gap-of-almost-2-billion | title=Coronavirus Vaccine Work Faces Funding Gap of Almost $2 Billion | author=James Paton | date=6 March 2020 | accessdate=8 March 2020 | website=[[Bloomberg News]]}}</ref>\n\nIn March 2020, CEPI invested US$4.4 million in two more projects with Swedish vaccine laboratory [[Novavax]], and with [[Oxford University]], bringing its total investment in SARS-CoV-2 vaccine work to US$23.7 million, and announcing that it would invest up to US$100 million in further COVID-19 projects.<ref name=RT2>{{cite website| url=https://www.reuters.com/article/us-health-coronavirus-vaccines-cepi/epidemic-response-group-ups-coronavirus-vaccine-funding-to-23-7-million-idUSKBN20X1PO | website=[[Reuters News]] | author=Kate Kelland | date=9 March 2020 | accessdate=9 March 2020 | title=Epidemic response group ups coronavirus vaccine funding to $23.7 million}}</ref>\n\n====Chikungunya virus====\n[[File:Emd-5577.jpg|thumb|[[Transmission electron cryomicroscopy|Cryo-TEM]] of [[Chikungunya virus|Chikungunya]]]]\nIn June 2019, US$21 million was given to Themis Bioscience to fund [[phase 3 clinical trial]]s and regulatory approval of a vaccine using measles viral vector technology.<ref name=ER/>\n\nIn July 2019, US$23.4 million was given to Austrian-based biotech [[Valneva SE]] to fund manufacturing and late-stage clinical development of a single-dose, live-attenuated vaccine.<ref name=ER/>\n\n====Rift Valley fever====\n\nIn July 2019, US$12.5 million was given to Dutch-based [[Wageningen University and Research]] for a single-dose vaccine candidate for Rift Valley fever that uses an attenuated virus technology, which included: vaccine manufacturing, preclinical research, and a phase 1 study.<ref name=ER/>\n\nIn July 2019, US$9.5 million was given to [[Colorado State University]] for manufacturing and preclinical studies to assess another single-dose vaccine candidate against Rift Valley fever (also using an attenuated virus technology).<ref name=ER/>\n\n==See also==\n*[[Centers for Disease Control and Prevention]] (CDC)\n*[[European Centre for Disease Prevention and Control]]\n\n==References==\n{{reflist|refs=\n<ref name=\"Guardian_CEPI_16weeks\">{{cite news | last1= Devlin | first1= Hannah | title= Lessons from Sars outbreak help in race for coronavirus vaccine | date= 2020-01-24 |newspaper= [[The Guardian]] | url= https://www.theguardian.com/science/2020/jan/24/lessons-from-sars-outbreak-help-in-race-for-coronavirus-vaccine |accessdate=2020-01-25 |archiveurl= https://web.archive.org/web/20200125203322/https://www.theguardian.com/science/2020/jan/24/lessons-from-sars-outbreak-help-in-race-for-coronavirus-vaccine |archivedate= 2020-01-25 |url-status=live <!-- live|dead|unfit|usurped --> |url-access = <!-- (subscription/registration/limited) default=free -->}}</ref><ref name=\"ThomReut_NIH_Moderna_3months\">{{cite news | last1= Steenhuysen | first1= Julie | last2= Kelland | first2= Kate | title= With Wuhan virus genetic code in hand, scientists begin work on a vaccine | date= 2020-01-24 | agency= [[Thomson Reuters]] | url= https://www.reuters.com/article/us-china-health-vaccines-idUSKBN1ZN2J8 |accessdate=2020-01-25 |archiveurl= https://web.archive.org/web/20200125203723/https://www.reuters.com/article/us-china-health-vaccines-idUSKBN1ZN2J8 |archivedate= 2020-01-25 |url-status=live <!-- live|dead|unfit|usurped --> |url-access = <!-- (subscription/registration/limited) default=free -->}}</ref>\n}}\n\n==External links==\n{{commons category}}\n* {{official|http://cepi.net }}\n* [https://www.youtube.com/watch?v=dcJDpV-igjs Dr Richard Hatchett Interview] [[Channel 4 News]] (6 March 2020)\n* [https://www.who.int/immunization/sage/meetings/2019/april/1_SAGE_April_2019_partners_Hatchett.pdf?ua=1 CEPI: Presentation to SAGE Meeting], [[World Health Organisation]] (4 April 2020)\n{{COVID-19|state=collapsed}}\n{{Wellcome Trust}}\n{{authority control}}\n\n[[Category:Infectious disease organizations]]\n[[Category:Epidemics]]\n[[Category:Organisations based in Oslo]]\n[[Category:Medical and health organisations based in Norway]]\n[[Category:2017 establishments in Norway]]\n[[Category:Non-profit organisations based in Norway]]\n[[Category:Bill & Melinda Gates Foundation]]\n[[Category:Wellcome Trust]]\n[[Category:Vaccine producers]]\n[[Category:Funding bodies]]\n[[Category:Health charities]]\n[[Category:Organizations associated with the 2019\u201320 coronavirus pandemic]]\n", "text_old": "{{Other uses|CEPI (disambiguation)|Cepi (disambiguation)}}\n{{short description|Public-private organization for vaccine development}}\n{{Infobox organization\n| name                = Coalition for Epidemic Preparedness Innovations\n| logo                = CEPI.svg\n| motto               = ''New vaccines for a safer world''\n| abbreviation        = CEPI\n| formation           = {{start date and age|2017|01}}\n| headquarters        = [[Oslo]], Norway\n| coordinates         = \n| additional_location = {{bulleted list\n  | [[London]], [[UK]]\n  | [[Washington D.C.]], [[U.S.]]\n}}\n| purpose             = Fund vaccine development<ref name=FT/>\n| founding_location   = [[Davos]], Switzerland.<ref name=FT/> \n| founders             = {{bulleted list\n  | [[The Wellcome Trust]]\n  | [[Bill and Melinda Gates Foundation]].<ref name=FT/> \n}}\n| leader_title        = Chief executive\n| leader_name         = Richard J. Hatchett\n| leader_title2       = \n| leader_name2        = \n| board_of_directors  = \n| key_people          = [[Jane Halton]] (Chair)\n| main_organ          = \n| staff               = 68<ref name=BB>{{cite website|url=https://www.bloomberg.com/news/articles/2020-02-13/this-oslo-facility-may-be-the-key-to-the-coronavirus-vaccine | title=The Road to a Coronavirus Vaccine Runs Through Oslo | website=[[Bloomberg News]] | author=Peter Coy | date=13 February 2020 | accessdate=7 March 2020}}</ref>\n| staff_year          = 2020\n| website             = {{URL|https://cepi.net|CEPI.net}}\n}}\nThe '''Coalition for Epidemic Preparedness Innovations''' ('''CEPI''') is a foundation that takes donations from public, private, philanthropic, and [[civil society]] organisations, to finance independent research projects to develop [[vaccine]]s against [[emerging infectious disease]] (EID).<ref name=BB/><ref name=ER/> CEPI is focused on the [[World Health Organisation]]'s (WHO) \"[[blueprint priority disease]]s\", which includes: the [[Middle East respiratory syndrome-related coronavirus]] ([[MERS-CoV]]), the [[Severe acute respiratory syndrome coronavirus 2]] ([[SARS-CoV-2]]), the [[Nipah virus]], the [[Lassa fever virus]], and the [[Rift Valley fever]] virus, as well as the [[Chikungunya virus]] and the hypothetical, unknown pathogen \"[[Disease X]]\".<ref name=\"BUND\" /><ref name=\"ER\" /> CEPI investment also requires \"equitable access\" to the vaccines during [[outbreak|outbreaks]].<ref name=science/>\n\nCEPI was conceived in 2015 and formally launched in 2017 at the [[World Economic Forum]] (WEF) in [[Davos]], Switzerland.  It was co-founded and co-funded with US$460 million from the [[Bill and Melinda Gates Foundation]], [[The Wellcome Trust]], and a consortium of nations, being Norway, Japan, Germany; to which the European Union (2019) and Britain (2020) subsequently joined.<ref name=\"FT\" /><ref name=\"ER\" />  CEPI is headquartered in [[Oslo]], Norway.<ref name=FT/><ref name=BB/><ref name=ER/>  In 2017, ''[[Nature (journal)|Nature]]'' said, \"It is by far the largest vaccine development initiative ever against viruses that are potential epidemic threats\".<ref name=NAT/> In 2020, CEPI was identified as a \"key player in the race to develop a vaccine\" for the [[Coronavirus disease 2019]].<ref name=BB/><ref name=GUARD/><ref name=FT2/> \n\n==History==\n\n===Founding===\n[[File:Jeremy Farrar C0058569 Wellcome Images.jpg|thumb|upright=0.7|[[Jeremy Farrar]], co-author of the concept of CEPI, and board member]]\n\nThe concept for CEPI was outlined in a July 2015 paper in ''[[The New England Journal of Medicine]]'', titled \"Establishing a Global Vaccine-Development Fund\", co-authored by British medical researcher [[Jeremy Farrar]] (a director of [[Wellcome Trust]]), American physician [[Stanley A. Plotkin]] (co-discoverer of the [[Rubella]] vaccine), and American expert in infectious diseases [[Adel Mahmoud]] (developer of the [[HPV vaccine]] and [[rotavirus vaccine]]).<ref name=science/><ref>{{cite journal | title=Establishing a Global Vaccine-Development Fund | journal=[[The New England Journal of Medicine]] | date=23 July 2015 | author1=Stanley A. Plotkin | author2= Adel A.F. Mahmoud | author3=Jeremy Farrar | doi= 10.1056/NEJMp1506820 |pmid = 26200974| pages=297\u2013300 | volume=373|issue = 4}}</ref>\n\nTheir concept was further expanded at the 2016 WEF in Davos, where it was discussed as a solution to the problems encountered in developing and distributing a vaccine for the [[Western African Ebola virus epidemic]].<ref name=FT/>  Co-founder and funder, [[Bill Gates]] said: \"The market is not going to solve this problem because epidemics do not come along very often \u2014 and when they do you are not allowed to charge some huge premium price for the tools involved\".<ref name=FT/>  CEPI's creation was also supported and co-funded by the pharmaceutical industry including [[GlaxoSmithKline]] (GSK), with CEO [[Andrew Witty|Sir Andrew Witty]] explaining at the WEF, \"It is super-disruptive when the red phone rings in our vaccine division because of a health emergency.  People do not realise that there's no spare capacity in the world's vaccine production system today\".<ref name=FT/>\n\nCEPI was formally launched at the 2017 WEF in Davos, with an initial investment of US$460 million by a consortium that included the governments of Norway, Japan, and Germany, The Wellcome Trust, and the [[Bill and Melinda Gates Foundation|Gates Foundation]];<ref name=TIME>{{cite magazine | url=https://time.com/4639245/cepi-ebola-zika-epidemic/ | title=This New Group Wants to Stop Pandemics Before They Start | magazine=[[Time (magazine)|Time]] | author=Alexandra Sifferlin | date=19 January 2017}}</ref><ref name=FT>{{cite newspaper | url=https://www.ft.com/content/5699ac84-dd87-11e6-86ac-f253db7791c6 | title=Davos launch for coalition to prevent epidemics of emerging viruses | newspaper=[[Financial Times]] | author=Clive Cookson | date=18 January 2017 | accessdate=6 March 2020 | quote=Billion-dollar programme aims to cut vaccine-development time from 12 years to one}}</ref>  India joined a short time afterwards.<ref>{{cite news|first=James|last=Paton|date=January 18, 2017|url=https://www.bloomberg.com/news/articles/2017-01-18/ebola-zika-push-drugmakers-to-join-effort-to-avert-pandemics|title=Ebola, Zika Push Drugmakers Into Effort to Avert Pandemics|work=[[Bloomberg L.P.|Bloomberg]]}}</ref><ref name=economist>{{cite journal|journal=[[The Economist]]|title=Putting shots in the locker|date=3 September 2016|pages=67\u201368|volume=420|number=9003|url=https://www.economist.com/news/science-and-technology/21706240-how-anticipate-epidemics-putting-shots-locker}}</ref>  In a launch interview with the ''[[Financial Times]]'' (FT), Gates said that a key goal was to reduce the time to develop vaccines from 10 years to less than 12 months.<ref name=FT/>  The initial targets were the six EID viruses with known potential to cause major epidemics, being: [[Middle East respiratory syndrome|MERS]], [[Lassa fever]], [[Nipah virus]], [[Ebola]], [[Marburg fever]] and [[Zika]].<ref name=FT/><ref name=ER>{{cite journal | author1=Dimitrios Gouglas | author2= Mario Christodoulou | author3= Stanley A Plotkin | author4= Richard Hatchett | title=CEPI: Driving Progress Towards Epidemic Preparedness And Response | journal=[[Epidemiologic Reviews]] | doi=10.1093/epirev/mxz012 | pmid= 31673694 | date=November 2019}}</ref> The ''FT'' reported CEPI would \"build the scientific and technological infrastructure for developing vaccines quickly against pathogens that emerge from nowhere to cause a global health crisis, such as Sars in 2002/03 and Zika in 2015/16\", and fund research papers on the costs and process of vaccine development.<ref name=FT/> ''[[Town & Country (magazine)|Town & Country]]'' listed it as a \"Top 10 moment from Davos\".<ref>{{cite magazine | url=https://www.townandcountrymag.com/society/money-and-power/news/g3205/2017-davos-world-economic-forum/ | magazine=[[Town & Country (magazine)|Town & Country]] | title=The Top 10 Moments at the 2017 Davos World Economic Forum | author=Natalina Lopez | date=27 January 2017 | accessdate=13 March 2020}}</ref>\n\nAt launch, Norwegian physician [[John-Arne R\u00f8ttingen]], who led the steering committee for Ebola vaccine trials, served as interim CEO, and CEPI was based at the [[Norwegian Institute of Public Health]] in Olso.<ref name=science>{{cite journal|author=John Cohen|date=2 September 2016|title=New vaccine coalition aims to ward off epidemics|url=http://www.sciencemag.org/news/2016/09/new-vaccine-coalition-aims-ward-epidemics|journal=Science|volume=353|issue=6303}}</ref>\n\nIn April 2017, Richard J. Hatchett, former director of the U.S. government's [[Biomedical Advanced Research and Development Authority]] (BARDA), became the full-time CEO.<ref>{{cite journal| journal=[[International AIDS Vaccine Initiative|IAVIReport]] | url=https://www.iavireport.org/vol-21-no-1-2017/1879-an-interview-with-richard-hatchett | title=AN INTERVIEW WITH RICHARD HATCHETT | volume=21 | issue=1 | date=2017 |  author=Michael Dumiak}}</ref>  Hatchett was also a member of the [[United States Homeland Security Council]] under [[George W. Bush]], and the [[United States National Security Council]], under [[Barack Obama]].<ref name=FT2/><ref>{{cite website | url=https://www.lshtm.ac.uk/newsevents/events/richard-hatchett-lshtm | title=Richard Hatchett at LSHTM | website=[[London School of Hygiene & Tropical Medicine]] | accessdate=8 March 2020}}</ref>\n\nIn April 2017, CEPI opened an additional office in London, and in October 2017, a further office was opened in Washington D.C.<ref>{{cite website|title=Coalition for Epidemic Preparedness Innovations | url=https://cepi.net/about/whyweexist/ | accessdate=11 March 2020 | website=CEPI}}</ref>\n\n===Funding===\n[[File:Coalition for Epidemic Preparedness Innovations (2017, Davos).jpg|thumb|Launch during the 2017 WEF at Davos]]\n\nAt its launch in 2017, CEPI announced five-year financial pledges from its founders that amounted to US$460 million and came from the sovereign governments of Japan (US$125 million), Norway (US$120 million), and Germany (US$10.6 million in 2017 alone, and which later became US$90 million), and from global foundations of the Gates Foundation (US$100 million), and the Wellcome Trust (US$100 million); India was finalising their financial commitment, which was made shortly afterward.<ref name=WP2>{{cite newspaper | url=https://www.washingtonpost.com/news/to-your-health/wp/2017/01/18/new-global-coalition-launched-to-create-new-vaccines-prevent-epidemics/ | title=New global coalition launched to create vaccines, prevent epidemics | newspaper=[[Washington Post]] | author=Lena H. Sun | date=18 January 2017 | accessdate=12 March 2020}}</ref>  A funding target of US$1 billion was set for the first 5 years of operation (i.e. by January 2022).<ref name=WP2/>  The journal ''[[Nature (journal)|Nature]]'' said of the amount raised that: \"It is by far the largest vaccine development initiative ever against viruses that are potential epidemic threats\".<ref name=NAT>{{cite journal | title=Billion-dollar project aims to prep vaccines before epidemics hit | journal=[[Nature (journal)|Nature]] | date=18 January 2017 | doi=10.1038/nature.2017.21329 | pmid=28128262 | bibcode=2017Natur.541..444B | volume =541 | pages=444\u2013445| last1=Butler | first1=Declan | issue=7638 }}</ref>\n\nAs part of its funding structure, CEPI has used \"vaccine bonds\" to \"frontload\" multi-year sovereign funding pledges. In 2019, the [[International Finance Facility for Immunisation]] (IFFIm) issued NOK 600 million in vaccine bonds to front-load the commitment by Norway, through [[GAVI|Gavi, the Vaccine Alliance]], to CEPI.<ref>{{cite website | url=https://www.gavi.org/news/media-room/coalition-epidemic-preparedness-innovation-turns-iffim-accelerate-funding-new | title=Coalition for Epidemic Preparedness Innovation turns to IFFIm to accelerate funding for new vaccine development | date=12 December 2018 | website=[[GAVI]] | accessdate=8 March 2020 | quote=Under the just-approved arrangement, IFFIm will, on CEPI\u2019s behalf, issue bonds on international capital markets supported by new pledges from the Kingdom of Norway, which hosts CEPI. Norway and CEPI have turned to IFFIm because of its simplicity, speed of execution, cost, compliance and strong reputation among investors.}}</ref><ref>{{cite website | url=https://iffim.org/press-releases/iffim-issues-nok600-million-vaccine-bonds | title=IFFIm issues NOK600 million Vaccine Bonds | website=[[International Finance Facility for Immunisation]] | accessdate=8 March 2020 | date=18 July 2019}}</ref>\n\nIn March 2019, the [[European Commission]] granted access to CEPI into the EU's [[Horizon 2020]] programme, and a longer-term financial funding programme.<ref>{{cite website | url=https://cordis.europa.eu/programme/id/H2020_FPA-SC1-CEPI-2019 | website=[[European Commission]] | accessdate=9 March 2020 | date=19 March 2019 | title=FPA-SC1-CEPI-2019 - Grant to the Coalition for Epidemic Preparedness Innovations (CEPI) }}</ref>  CEPI note presentations that the EU's financial commitment amounts to US$200 million, which when added to the seed amount (including the full German commitment), came to US$740 million.<ref>{{cite website | url=https://www.uniteforsight.org/conference/ppt-2019/Dimitrios%20Gouglas%20PDF.pdf | title=[PRESENTATION] Coalition for Epidemic Preparedness Innovations | date=13 April 2019 | accessdate=12 March 2020 | author=Dimitrios Gouglas | website=[[Unite For Sight]]}}</ref>\n\nBy February 2020, ''[[Bloomberg News]]'' reported that CEPI had raised a total of US$760 million with additional donations from the governments of Australia, Belgium, Canada, and the U.K.<ref name=BB/>  ''Bloomberg'' said that \"CEPI solves what economists call a 'coordination problem'. It can help pair boutique research and development companies with big vaccine manufacturers, work with regulators to streamline approval processes and resolve patent disputes on the spot. Its scientific advisory committee has executives from Pfizer, Johnson & Johnson, and Japan's Takeda Pharmaceutical, among others\".<ref name=BB/>\n\nIn March 2020, the British government pledged \u00a3210 million in funding to CEPI to specifically focus on a vaccine for the coronavirus; making Britain CEPI's largest individual donor.<ref>{{cite newspaper | url=https://www.thetimes.co.uk/article/uk-promises-210m-to-find-coronavirus-vaccine-7883gcq7q | title=UK promises \u00a3210m to find coronavirus vaccine | author=Rhys Blakely | newspaper=[[The Times]] | date=27 March 2020 | accessdate=28 March 2020}}</ref><ref>{{cite newspaper | url=https://www.independent.co.uk/news/uk/politics/coronavirus-vaccine-boris-johnson-uk-donation-update-a9428566.html | title=Coronavirus: Britain now the largest contributor to international effort to find vaccine after \u00a3210m commitment | newspaper=[[The Independent]] | author=Andrew Woodcock | date=27 March 2020 | accessdate=28 March 2020}}</ref>\n\n===Equitable access===\nOne of the founding principles of CEPI is around what it calls \"equitable access\" by charging vaccines at affordable prices to developing nations.<ref name=BB/>  CEPI's original 18-page policy document gave  CEPI \"step-in\" rights to use the intellectual property of its partner companies in which it had invested, for vaccine production even if they withdrew from the CEPI agreement.<ref name=BB/>  However, part of this policy had to be later scaled back into a shorter, two-page, document in order to encourage more private sector partner companies to engage in vaccine research.<ref name=BB/>  CEPI came under criticism for this by [[M\u00e9decins Sans Fronti\u00e8res]], however, commentators expressed an opinion that this may have been an inevitable consequence to get higher engagement by the pharmaceutical industry in supporting vaccine development.<ref>{{cite newspaper | url=https://www.nytimes.com/2020/03/02/opinion/contributors/pharma-vaccines.html | title=Big Pharma May Pose an Obstacle to Vaccine Development | date=2 March 2020 | accessdate=8 March 2020 | newspaper=[[New York Times]] | author=Gerald Posner | quote=Drug companies on CEPI's scientific advisory panel, including Johnson & Johnson, Pfizer, and Japan's Takeda, pushed back. CEPI mostly capitulated in a December 2018 two-page declaration in which it jettisoned specifics but gave lip service to its founding mission of \"equitable access to these vaccines for affected populations during outbreaks.\"| author-link=Gerald Posner }}</ref>\n\n==Structure==\n[[File:Dr Richard J. Hatchett (2011).jpg|thumb|upright=0.7|Richard J. Hatchett, CEO of CEPI from 2017]]\nCEPI is a Norwegian Association, and had the following governance structure as at March 2020:<ref name=CEPI/><ref name=ER/>\n\n*Leadership. Staff of 68,<ref name=BB/> that runs the organisation on a day-to-day basis under the direction of a chief executive officer,  Richard Hatchett.<ref name=CEPI/>\n*Board. Twelve members, four from the Investors Council, and eight of which are \"independent members representing competencies including industry, global health, science, resource mobilisation, finance\".<ref name=CEPI/>  \n**[[Charlotte Watts]], chief scientific adviser to the U.K. [[Department for International Development]]\n**Cherry Gagandeep Kang, [[Christian Medical College & Hospital, Vellore]]\n**David Reddy, [[Medicines for Malaria Venture]]\n**Ichiro Kurane, National Institute of Infectious Diseases, Japan\n**Joachim Klein, [[Federal Ministry of Education and Research (Germany)]]\n**[[Jane Halton]], chairperson\n**[[Jeremy Farrar]], director of the Wellcome Trust\n**John Nkengasong, Africa Centers for Disease Control and Prevention\n**Nadine Gbossa, representative Nigeria, [[International Fund for Agricultural Development]]\n**Patricia J. Garc\u00eda, former [[Ministry of Health (Peru)|Minister of Health, Peru]]\n**[[Peter Piot]], [[London School of Hygiene & Tropical Medicine]]\n**Rajeev Venkayya, [[Takeda Pharmaceutical Company]]\n**(Attending board meetings are an additional five non-voting members that include: [[Helen Rees]], [[Muhammad Ali Pate]], [[Margaret Hamburg|Margaret \"Peggy\" Hamburg]], [[Soumya Swaminathan (scientist)|Soumya Swaminathan]], the CEPI CEO).<ref name=CEPI/>\n*Scientific Advisory Committee (SAC). 24 voting members that provide \"scientific support, advice, and guidance to the CEPI Board and Secretariat. Final decision-making about the issues addressed by the committee rests with the Board or the Secretariat\".  The SAC includes members such as [[Alash\u2019le Abimiku]], [[Christian Br\u00e9chot]], [[Delese Mimi Darko]], [[Helen Rees]], [[James C. Robinson (health economist)|James C. Robinson]] (vice-chair), [[Kathleen Neuzil]], {{ill|Myron M. Levine|de|Myron M. Levine}}, [[Peter Smith (epidemiologist)|Peter Smith]], [[Stanley Plotkin]], [[Thomas Kariuki]], and [[Yves L\u00e9vy]].  In addition, there are five non-voting members of the SAC, who each represent mostly industry, being [[Johnson & Johnson]], [[Takeda Pharmaceutical]], [[Pfizer]], and [[Sanofi Aventis]]; with the final non-voting member being from the WHO.<ref name=CEPI/>\n*Joint coordination group (JAG). The JAG is a \"roundtable of independent institutions with an interest in seeing CEPI\u2019s vaccines successfully developed and deployed in an outbreak\". Members of the JAG included the WHO, [[GAVI]], [[European Medicines Agency]], [[Food and Drug Administration]], [[M\u00e9decins Sans Fronti\u00e8res]], [[UNICEF]], [[International Federation of Red Cross and Red Crescent Societies]], African Vaccine Regulatory Forum, [[National Institute for Biological Standards and Control]], and The Wellcome Trust.<ref name=CEPI>{{cite website| url=https://cepi.net/about/whoweare/ | title=Who we are | website=Coalition for Epidemic Preparedness Innovations | accessdate=9 March 2020}}</ref>\n*Investors Council (IC). The IC nominates four investor representatives to the board, and its approval is required for single investments over US$100 million. The IC included representatives from the governments of Norway, UK, Germany, Japan, Canada, Ethiopia, Australia, Belgium, the EU, and the Gates Foundation and the Wellcome Trust.<ref name=CEPI/>\n\n==Publications==\nIn October 2018, CEPI published a study in British healthcare journal ''[[The Lancet]]'', that estimated the costs of developing vaccines for diseases that could escalate into global humanitarian crises.  The study focused on 11 diseases which cause relatively few deaths at present and primarily strike the poor. The authors estimated that it would cost between US$2.8 billion and US$3.7 billion to develop at least one vaccine for each of the diseases. This should be set against the potential cost of an outbreak. The 2003 SARS outbreak in East Asia cost US$54 billion.<ref>{{cite news |title=Scientists have estimated the cost of stopping 11 diseases that could kill millions in a pandemic |url=https://www.vox.com/future-perfect/2018/10/22/17999676/vaccine-ebola-pandemic-disease-zika-epidemic-sars?platform=hootsuite |accessdate=2 December 2018 |publisher=Vox |date=22 October 2018}}</ref><ref>{{cite journal | url=https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(18)30346-2/fulltext | title=Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study | journal=The Lancet | year=2018 | volume=6 | issue=12 | pmid=30342925 | last1=Gouglas | first1=D. | last2=Thanh Le | first2=T. | last3=Henderson | first3=K. | last4=Kaloudis | first4=A. | last5=Danielsen | first5=T. | last6=Hammersland | first6=N. C. | last7=Robinson | first7=J. M. | last8=Heaton | first8=P. M. | last9=R\u00f8ttingen | first9=J. A. | pages=e1386\u2013e1396 | doi=10.1016/S2214-109X(18)30346-2 }}</ref>\n\nIn November 2019, CEPI published a paper in the German healthcare journal ''{{ill|Bundesgesundheitsblatt|de|Bundesgesundheitsblatt}}'', discussing the structure and operation of CEPI and that its target portfolio was on the [[World Health Organisation|W]]Gat's \"[[blueprint priority disease]]s\", that included: MERS-CoV, Nipah virus, Lassa fever virus, and [[Rift Valley fever]] virus, as well as [[Chikungunya virus]], and the WHO's [[Disease X]].<ref name=BUND>{{cite journal | title=Developing vaccines against epidemic-prone emerging infectious diseases | journal=Bundesgesundheitsblatt | pages=65\u201373 | volume=63 | doi=10.1007/s00103-019-03061-2| pmid=31776599 | pmc=6925075 |year = 2020|last1 = Bernasconi|first1 = Valentina|last2 = Kristiansen|first2 = Paul A.|last3 = Whelan|first3 = Mike|last4 = Rom\u00e1n|first4 = Ra\u00fal G\u00f3mez|last5 = Bettis|first5 = Alison|last6 = Yimer|first6 = Solomon Abebe|last7 = Gurry|first7 = C\u00e9line|last8 = Andersen|first8 = Svein R.|last9 = Yeskey|first9 = Debra|last10 = Mandi|first10 = Henshaw|last11 = Kumar|first11 = Arun|last12 = Holst|first12 = Johan|last13 = Clark|first13 = Carolyn|last14 = Cramer|first14 = Jakob P.|last15 = R\u00f8ttingen|first15 = John-Arne|last16 = Hatchett|first16 = Richard|last17 = Saville|first17 = Melanie|last18 = Norheim|first18 = Gunnstein| issue=1 }}</ref>\n\nIn November 2019, CEPI also published a paper in the healthcare journal ''[[Epidemiologic Reviews]]'', outlining all of the projects they had invested in and their scientific and medical rationale.  The paper also updated CEPI's priorities saying that in addition to investing in vaccines for its target portfolio, it also wanted to fund the establishment of technical and regulatory pathways for vaccine development, develop sustainable manufacturing solutions for vaccine candidates nearing completion, and create investigational stockpiles of its vaccine candidates for use in emergency situations.<ref name=ER/>\n\n==Investments==\n\nMost of CEPI's work is performed by allocating funds to independent third-party laboratories and vaccine research organizations through investments, the most material ones being:<ref name=BB/><ref name=ER/>\n\n===General development===\n\nIn December 2018, US$8.4 million to [[Imperial College]] in London, to fund the development of a \"self-amplifying RNA vaccine platform\" that CEPI said: \"would enable a tailored vaccine production against multiple viral pathogens (including H1N1 influenza, rabies virus, and Marburg virus)\".<ref name=ER/>  \t\n\nIn December 2018, US$10.6 million was given to the [[University of Queensland]] to fund the development of a \"[[molecular clamp]]\" vaccine platform, that CEPI described as a \"transformative technology that enables targeted and rapid vaccine production against multiple viral pathogens (including influenza virus, MERS-CoV, and respiratory syncytial virus)\".<ref name=ER/> \t\n\nIn February 2019, US$34 million was given to the German-based [[CureVac]] [[biopharmaceutical]] company, to fund the development of an \"RNA Printer prototype\", which CEPI described as being a \"transportable, down-scaled, automated [[mRNA]] printing facility, that can produce rapidly, a supply of lipid-nanoparticle\u2013formulated mRNA vaccine candidate that can target known pathogens (including Lassa fever, yellow fever, and rabies); and prepare for rapid response to unknown pathogens (i.e., [[Disease X]])\".<ref name=ER/>\n\n===Specific vaccines===\n\n====Lassa fever/MERS-CoV====\n[[File:Lassa virus.JPG | thumb | [[Transmission electron microscopy|TEM]] of [[Lassa fever|Lassa]] [[virions]]]]\nIn March 2018, US$37.5 million was given to Austrian-based Themis Bioscience to fund a vaccine against Lassa virus and MERS-CoV, using a measles vector technology.<ref>{{Cite news|url=https://www.businesswire.com/news/home/20180306005125/en/CEPI-Partners-Themis-Bioscience-Advance-Vaccines-Lassa|title=CEPI Partners with Themis Bioscience to Advance Vaccines Against Lassa Fever and MERS \u2013 Press Release|access-date=2018-04-15|language=en}}</ref><ref name=ER/>\n\nIn April 2018, US$56 million was given to U.S.-based [[Inovio Pharmaceuticals]] to fund a DNA-vaccine against Lassa virus and MERS-CoV.<ref>{{Cite news|url=https://globenewswire.com/news-release/2018/04/11/1468470/0/en/Inovio-Awarded-up-to-56-Million-from-CEPI-to-Advance-DNA-Vaccines-Against-Lassa-Fever-and-MERS.html|title=Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS \u2013 Press Release|work=GlobeNewswire News Room|access-date=2018-04-15|language=en-US}}</ref><ref name=ER/>\n\nIn May 2018, US$54.9 million was given to the [[International AIDS Vaccine Initiative]] (IAVI), to fund a vaccine against Lassa virus via replication-competent vesicular stomatitis [[viral vector]] technology.<ref name=ER/>\n\nIn June 2018, US$35 million was given to U.S.-based Profectus Biosciences, to fund an attenuated \"VesiculoVax\" vaccine against Lassa virus.<ref name=ER/>\n \nIn August 2018, US$36 million was given to German-based {{ill|IDT Biologika|de|IDT Biologika}}, to fund a vaccine against MERS-CoV (only) using a recombinant modified vaccinia Ankara viral vector technology.<ref name=ER/>\n \nIn September 2018, US$19 million to [[Janssen Pharmaceutica]] and the [[University of Oxford]], to fund a vaccine against Lassa and MERS-Cov using a simian adenoviral vaccine viral vector technology.<ref name=ER/>\n\n====Nipah virus====\n[[File:Nipah.jpg | thumb | [[Transmission electron microscopy|TEM]] of [[Nipah virus|Nipah]] [[virions]]]]\n\nIn May 2018, US$25 million was given to U.S.-based Profectus Biosciences, to make a recombinant [[protein subunit]] vaccine against Nipah virus.<ref name=ER/>\n\nIn February 2019, US$31 million was given to the [[University of Tokyo]], to develop a vaccine by inserting the Nipah-virus G gene (\"Malaysia strain\"), into a measles vector (\"Edmonston B strain\").<ref name=ER/>\n\nIn August 2019, US$43.6 million was given to Public Health Vaccines LLC, to fund the development and manufacture of a vaccine using a recombinant vesicular stomatitis virus technology.<ref>{{cite website | url=https://cepi.net/news_cepi/cepi-awards-up-to-us43-6-million-to-public-health-vaccines-llc-for-development-of-a-single-dose-nipah-virus-vaccine-candidate/ | website=CEPI | date=19 August 2019 | accessdate=9 March 2020 | title=CEPI awards up to US$43.6 million to Public Health Vaccines, LLC. for development of a single-dose Nipah virus vaccine candidate}}</ref><ref name=ER/>\n\n====SARS-CoV-2====\n{{see also|2019\u201320 coronavirus pandemic|Coronavirus disease 2019#Research}}\n[[File:SARS-CoV-2 49531042877.jpg|thumb|[[Scanning electron microscope|SEM]] of [[SARS-CoV-2]]]]\n\nIn January 2020, CEPI funded three teams working on a [[COVID-19 vaccine|vaccine]] for [[SARS-CoV-2]], being: [[Moderna]], [[Inovio Pharmaceuticals]], and the [[University of Queensland]] (UQ).<ref name=\"ThomReut_NIH_Moderna_3months\" /><ref name=\"Guardian_CEPI_16weeks\" /> By February 2020, Inovio announced that it had produced a pre-clinical [[DNA vaccination|DNA-based vaccination]] to fight [[COVID-19]] at its lab in [[San Diego]].<ref>{{cite web |title=Is a vaccine for the coronavirus coming? Inovio says it has designed one in San Diego |url=https://www.latimes.com/business/story/2020-02-15/coronavirus-vaccine-design-inovio-san-diego |website=[[Los Angeles Times]] |date=15 February 2020 |accessdate=17 February 2020}}</ref> Inovio collaborated with a Chinese firm to speed its acceptance by regulatory authorities in China for human trialing.<ref>{{Cite news |url=https://www.bbc.com/news/health-51299735 |title=Coronavirus: Scientists race to develop a vaccine |last=Mazumdar |first=Tulip |date=30 January 2020|website=[[BBC News Online]]|access-date=3 February 2020|archive-url=https://web.archive.org/web/20200130184311/https://www.bbc.com/news/health-51299735 |archive-date=30 January 2020 |url-status=live | name-list-format=vanc}}</ref> The strategy of the UQ team is to develop a [[molecular clamp]] vaccine that genetically modifies viral proteins to make them mimic the coronavirus and stimulate an immune reaction.<ref name=\"Guardian_CEPI_16weeks\" /><ref name=\"ThomReut_NIH_Moderna_3months\" />\n\nIn January 2020, CEPI announced a fourth SARS-CoV-2 project in a collaboration with their existing partner [[CureVac]], to develop and manufacture a vaccine.<ref>{{cite news |title=CureVac and CEPI extend their Cooperation to Develop a Vaccine against Coronavirus nCoV-2019 |url=https://www.curevac.com/news/curevac-and-cepi-extend-their-cooperation-to-develop-a-vaccine-against-coronavirus-ncov-2019 |accessdate=25 February 2020 |publisher=CureVac AG |date=31 January 2020}}</ref>  CEPI's CEO, Richard J. Hachett said in an interview with the ''FT'' that CEPI expected to have human trials within 16 weeks, but cautioned \"All these timelines are aggressive and aspirational. As circumstances unfold there may be opportunities to reduce the timing but it is critically important that any new vaccine is safe and effective\".<ref name=FT2>{{cite newspaper | url=https://www.ft.com/content/40abf052-41e9-11ea-bdb5-169ba7be433d | title=The scientist leading the coronavirus vaccine race | newspaper=[[Financial Times]] | date=30 January 2020 | accessdate=8 March 2020 | author=Hannah Kuchler}}</ref>\n\n[[File:2019-nCoV-CDC-23312 without background.png |thumb|[[Morphology (biology)|morphology]] of [[coronavirus]]]]\n\nIn February 2020, ''Bloomberg News'', citing [[virologists]], identified CEPI as a \"key player in the race to develop a vaccine\";<ref name=BB/> a status other media outlets have attributed.<ref>{{cite website | url=https://www.businessinsider.com/vaccines-for-wuhan-china-cornonavirus-moderna-inovio-cepi-2020-1?r=US&IR=T | title=A coalition backed by Bill Gates is funding biotechs that are scrambling to develop vaccines for the deadly Wuhan coronavirus | author=Andrew Dunne | website=[[Business Insider]] | date=23 January 2020 | accessdate=8 March 2020}}</ref><ref name=FT2/>  In reviewing vaccine development on the virus ''[[Vox (website)|Vox]]'' said: \"CEPI is a large part of why there are already dozens of Covid-19 vaccine candidates making their way through animal and human trials, as well as platforms to develop more\",<ref>{{cite magazine | url=https://www.vox.com/science-and-health/2020/3/4/21154590/coronavirus-vaccine-treatment-covid-19-drug-cure | title=A simple guide to the vaccines and drugs that could fight coronavirus | magazine=[[Vox (website)|Vox]] | date=6 March 2020 | accessdate=8 March 2020 | author1=Julia Belluz | author2= Umair Irfan | author3= Brian Resnick | quote=Knowing there will be more Ebola-like emergencies in need of ready vaccines was the starting point for the Coalition for Epidemic Preparedness Innovations, or CEPI, a public-private partnership that launched in 2017. Their raison d\u2019\u00eatre: to award grants for swift vaccine development targeting emerging threats that the pharmaceutical industry might otherwise ignore.}}</ref> while ''[[The Guardian]]'' said CEPI was \"leading efforts to finance and coordinate Covid-19 vaccine development\".<ref name=GUARD>{{cite newspaper | url=https://www.theguardian.com/world/2020/mar/15/when-will-a-coronavirus-vaccine-be-ready-human-trials-global-immunisation | title=When will a coronavirus vaccine be ready? | newspaper=[[The Guardian]] | date=15 March 2020 | accessdate=15 March 2020 | author=Laura Spinney | quote=\"The speed with which we have [produced these candidates] builds very much on the investment in understanding how to develop vaccines for other coronaviruses\", says Richard Hatchett, CEO of the Oslo-based nonprofit the Coalition for Epidemic Preparedness Innovations (Cepi), which is leading efforts to finance and coordinate Covid-19 vaccine development.}}</ref>\n\nIn March 2020, Hatchett gave an interview to ''[[Channel 4 News]]'' saying that \"war is an appropriate analogy\", for the steps needed to counter the virus, and that \"this is the most frightening disease that I have ever encountered in my career, and that includes Ebola, it includes MERS, it includes SARS. And it's frightening because of the combination of infectiousness and a lethality that appears to be manyfold higher than flu\".<ref>{{cite website | url=https://www.channel4.com/news/this-is-the-most-frightening-disease-ive-ever-encountered-virus-expert-dr-richard-hatchett | quote=Dr. Richard Hatchett advised the Bush and Obama White Houses and worked for the agency that protects Americans against pandemics and bioweapons. | title='This is the most frightening disease I've ever encountered' \u2013 virus expert Dr. Richard Hatchett | author=Matt Frei | website=[[Channel 4 News]] | date=6 March 2020 | accessdate=8 March 2020 | series=Interview on C4 News [VIDEO]| author-link=Matt Frei }}</ref>  Hatchett told ''[[The Daily Telegraph]]'' that coronaviruses are the most serious threat to public health since the [[Spanish flu]], and that a vaccine will take up to 18 months to deliver at a cost of \u00a31.5 billion.<ref>{{cite newspaper|url=https://www.telegraph.co.uk/news/2020/03/06/coronavirus-poses-serious-threat-public-health-since-spanish/ | title=Coronavirus poses most serious threat to public health since Spanish flu pandemic, says expert | newspaper=[[Daily Telegraph]] | author=Robert Mendick | date=6 March 2020 | accessdate=7 March 2020}}</ref>    CEPI said that its funds for fighting the virus would be fully allocated by the end of March and that it was launching a new funding call for US$2 billion to support fighting the virus.<ref>{{cite website| url=https://www.reuters.com/article/us-health-coronavirus-vaccines/2-billion-needed-to-develop-covid-19-shot-says-epidemic-response-group-idUSKBN20T28H | title=$2 billion needed to develop COVID-19 shot, says epidemic response group | author=Kate Kelland | date=6 March 2020 | accessdate=7 March 2020 | website=[[Reuters News]]}}</ref><ref>{{cite newspaper | url=https://www.ft.com/content/e0ecc6b6-5d43-11ea-b0ab-339c2307bcd4 | title=Coronavirus and the $2bn race to find a vaccine | newspaper=[[Financial Times]] | date=5 March 2020 | accessdate=7 March 2020 | author=Hannah Kultcher}}</ref><ref>{{cite website | url=https://www.bloomberg.com/news/articles/2020-03-06/coronavirus-vaccine-work-faces-funding-gap-of-almost-2-billion | title=Coronavirus Vaccine Work Faces Funding Gap of Almost $2 Billion | author=James Paton | date=6 March 2020 | accessdate=8 March 2020 | website=[[Bloomberg News]]}}</ref>\n\nIn March 2020, CEPI invested US$4.4 million in two more projects with Swedish vaccine laboratory [[Novavax]], and with [[Oxford University]], bringing its total investment in SARS-CoV-2 vaccine work to US$23.7 million, and announcing that it would invest up to US$100 million in further COVID-19 projects.<ref name=RT2>{{cite website| url=https://www.reuters.com/article/us-health-coronavirus-vaccines-cepi/epidemic-response-group-ups-coronavirus-vaccine-funding-to-23-7-million-idUSKBN20X1PO | website=[[Reuters News]] | author=Kate Kelland | date=9 March 2020 | accessdate=9 March 2020 | title=Epidemic response group ups coronavirus vaccine funding to $23.7 million}}</ref>\n\n====Chikungunya virus====\n[[File:Emd-5577.jpg|thumb|[[Transmission electron cryomicroscopy|Cryo-TEM]] of [[Chikungunya virus|Chikungunya]]]]\nIn June 2019, US$21 million was given to Themis Bioscience to fund [[phase 3 clinical trial]]s and regulatory approval of a vaccine using measles viral vector technology.<ref name=ER/>\n\nIn July 2019, US$23.4 million was given to Austrian-based biotech [[Valneva SE]] to fund manufacturing and late-stage clinical development of a single-dose, live-attenuated vaccine.<ref name=ER/>\n\n====Rift Valley fever====\n\nIn July 2019, US$12.5 million was given to Dutch-based [[Wageningen University and Research]] for a single-dose vaccine candidate for Rift Valley fever that uses an attenuated virus technology, which included: vaccine manufacturing, preclinical research, and a phase 1 study.<ref name=ER/>\n\nIn July 2019, US$9.5 million was given to [[Colorado State University]] for manufacturing and preclinical studies to assess another single-dose vaccine candidate against Rift Valley fever (also using an attenuated virus technology).<ref name=ER/>\n\n==See also==\n*[[Centers for Disease Control and Prevention]] (CDC)\n*[[European Centre for Disease Prevention and Control]]\n\n==References==\n{{reflist|refs=\n<ref name=\"Guardian_CEPI_16weeks\">{{cite news | last1= Devlin | first1= Hannah | title= Lessons from Sars outbreak help in race for coronavirus vaccine | date= 2020-01-24 |newspaper= [[The Guardian]] | url= https://www.theguardian.com/science/2020/jan/24/lessons-from-sars-outbreak-help-in-race-for-coronavirus-vaccine |accessdate=2020-01-25 |archiveurl= https://web.archive.org/web/20200125203322/https://www.theguardian.com/science/2020/jan/24/lessons-from-sars-outbreak-help-in-race-for-coronavirus-vaccine |archivedate= 2020-01-25 |url-status=live <!-- live|dead|unfit|usurped --> |url-access = <!-- (subscription/registration/limited) default=free -->}}</ref><ref name=\"ThomReut_NIH_Moderna_3months\">{{cite news | last1= Steenhuysen | first1= Julie | last2= Kelland | first2= Kate | title= With Wuhan virus genetic code in hand, scientists begin work on a vaccine | date= 2020-01-24 | agency= [[Thomson Reuters]] | url= https://www.reuters.com/article/us-china-health-vaccines-idUSKBN1ZN2J8 |accessdate=2020-01-25 |archiveurl= https://web.archive.org/web/20200125203723/https://www.reuters.com/article/us-china-health-vaccines-idUSKBN1ZN2J8 |archivedate= 2020-01-25 |url-status=live <!-- live|dead|unfit|usurped --> |url-access = <!-- (subscription/registration/limited) default=free -->}}</ref>\n}}\n\n==External links==\n{{commons category}}\n* {{official|http://cepi.net }}\n* [https://www.youtube.com/watch?v=dcJDpV-igjs Dr Richard Hatchett Interview] [[Channel 4 News]] (6 March 2020)\n* [https://www.who.int/immunization/sage/meetings/2019/april/1_SAGE_April_2019_partners_Hatchett.pdf?ua=1 CEPI: Presentation to SAGE Meeting], [[World Health Organisation]] (4 April 2020)\n{{COVID-19|state=collapsed}}\n{{Wellcome Trust}}\n{{authority control}}\n\n[[Category:Infectious disease organizations]]\n[[Category:Epidemics]]\n[[Category:Organisations based in Oslo]]\n[[Category:Medical and health organisations based in Norway]]\n[[Category:2017 establishments in Norway]]\n[[Category:Non-profit organisations based in Norway]]\n[[Category:Bill & Melinda Gates Foundation]]\n[[Category:Wellcome Trust]]\n[[Category:Vaccine producers]]\n[[Category:Funding bodies]]\n[[Category:Health charities]]\n[[Category:Organizations associated with the 2019\u201320 coronavirus pandemic]]\n", "name_user": "Nulzilla", "label": "safe", "comment": "\u2192\u200ePublications:typos", "url_page": "//en.wikipedia.org/wiki/Coalition_for_Epidemic_Preparedness_Innovations"}
